clinical trial · NCT03697811
DE-117 Spectrum 5 Study
Primary Open-angle Glaucoma and Ocular HypertensionDE-117 Ophthalmic Solution
brief summary
Santen will evaluate the intraocular pressure (IOP) lowering effect and efficacy of DE-117 ophthalmic solution 0.002% in latanoprost low/non-responder subjects diagnosed with POAG or OHT
started
Sep 27, 2018
primary completion
Jan 13, 2022
completion
Jan 13, 2022
last updated
Aug 30, 2023
official title
An Open-Label, Multicenter Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution 0.002% in Latanoprost Low/Non-Responder Subjects Diagnosed With Primary Open-Angle Glaucoma or Ocular Hypertension - Spectrum 5 Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol